# OrganiGram Holdings Inc. (OGI.TO) fundamentals

Data as of 2026-09-08. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$1.59, market value C$229 million.

## Valuation
- **P/E (trailing): 2.6×**. OrganiGram Holdings Inc. trades at 2.6× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 48.3×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.80**. A PEG of 0.80 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.7×**. Each dollar of revenue is priced at 0.7×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 0.4×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **Free-cash-flow yield: -12.7%** (5-yr avg -14.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 37.7%**. The inverse of the P/E: 37.7% of the price is earned each year.

## Profitability
- **Gross margin: 2.2%**. OrganiGram Holdings Inc. keeps 2.2% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: -31.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -9.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -7.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -36.0%**. Return on all capital, debt included, is -36.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 15.4%**. Each dollar of assets produces 15.4% of profit.

## Growth
- **Revenue growth (1 yr): 62.2%** (3-yr 21.1%/yr, 5-yr 24.5%/yr). Revenue grew 62.2% over the last year, against 24.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 60.4%**. Earnings per share rose 60.4%, roughly in step with revenue.

## Financial health
- **Debt to equity: 0.03**. Debt is 0.03 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.7×**. It would take 2.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.26** (quick 1.28). Current assets cover the next year's liabilities 2.26 times.
- **Altman Z-score: 1.80**. A Z-score of 1.80 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. OrganiGram Holdings Inc. does not currently pay a dividend, but it returned -28.4% of its market value through buybacks over the last year.

## Price and momentum
- **Total return (1 yr): -27.7%** (YTD -31.2%, 3-mo 7.4%). The shares are down 27.7% over twelve months including dividends.
- **From 52-week high: -48.5%** (33.1% above the low). Trading 49% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.03** (volatility 60%). Beta of 1.03 against the S&P/TSX Composite: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OGI.TO · Page: https://foliofundamentals.com/stocks/ogi.to

Not investment advice.